Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 72

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 72
---
) |
| 2024               |     |          2,832,269 |     |          49,508,648 |     | 5.7%             |     |                                 $42,596 |
| 2023               |     |          2,015,046 |     |          43,734,253 |     | 4.6%             |     |                                 $46,302 |
| 2022               |     |          1,277,526 |     |          43,151,667 |     | 3.0%             |     |                                 $43,069 |
| Three-year average |     |          2,041,614 |     |                     |     | 4.4%             |     |                                 $43,989 |

<div align='center'>52</div>

We are committed to monitoring our equity burn rate and equity compensation share reserve. We will continuously seek to take appropriate action to reduce our burn rate, including evaluating the appropriate balance of stock options or restricted stock units (“RSUs”) awarded to lower the total number of shares granted.

We Manage Dilution Carefully

As of April 1, 2025, we had:

50,116,910 shares of common stock outstanding and 1,324,740 outstanding pre-funded warrants to purchase shares of common stock;

11,827,732 shares subject to outstanding options, with a weighted-average exercise price of $25.94 per share and a weighted-average remaining term of 6.4 years;

2,331,288 shares subject to outstanding RSUs; and

857,842 shares remaining available for future awards under our 2015 Plan, which prior to its expiration on June 17, 2025, would be the Company’s only equity plan eligible to grant future awards if the 2025 Plan is not approved.

Our outstanding awards as of April 1, 2025 amount to approximately 28.3% of our outstanding shares of common stock as of that date (or approximately 27.5% when giving effect to outstanding pre-funded warrants). However, our 11.8 million options outstanding as of April 1, 2025, or 83.5% of total awards outstanding, have a weighted-average exercise price of $25.94 per share, representing a multiple of approximately 3.8x over our closing stock price of $6.76 on April 1, 2025. This overhang, which includes a